Novartis AG
NVSEFOTCHealthcare● Active
$148.80
+$4.66(+3.23%)
Market Cap$283.9B
P/E Ratio—
52W High$171.29
52W Low$110.74
Novartis AG (NVSEF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
NVSEF · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 28, 2026EPS Actual
$1.99
Est. $2.10 · -5.2%
Revenue
$13.11B
Est. $13.46B · -2.6%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 28, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
NVSEF reports quarterly as a OTC-listed Drug Manufacturers - General company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 21, 2026 | $2.18 | — | — | — | $14.16B | — |
| ▼ Q2 FY2026 | Apr 28, 2026 | $2.10 | $1.99 | -5.2% | $13.11B | $13.46B | -2.6% |
| ▲ Q1 FY2026 | Feb 4, 2026 | $1.99 | $2.03 | +2.0% | $13.34B | $13.72B | -2.8% |
| ▼ Q3 FY2025 | Jul 17, 2025 | $2.35 | $2.06 | -12.3% | $14.84B | $13.68B | +8.5% |
| ▼ Q2 FY2025 | Apr 29, 2025 | $2.11 | $1.85 | -12.3% | $13.62B | $13.90B | -2.0% |
| ▼ Q1 FY2025 | Jan 31, 2025 | $1.80 | $1.41 | -21.7% | $13.56B | $12.84B | +5.6% |
| ▼ Q4 FY2024 | Oct 29, 2024 | $1.94 | $1.57 | -19.1% | $13.17B | $12.79B | +3.0% |
| ▼ Q3 FY2024 | Jul 18, 2024 | $1.85 | $1.59 | -14.1% | $12.59B | $12.45B | +1.1% |
Q3 FY2026
Jul 21, 2026
EPS Actual
—
EPS Est.
$2.18
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 28, 2026Miss
EPS Actual
$1.99
EPS Est.
$2.10
EPS Surpr.
-5.2%
Revenue
$13.11B
Q1 FY2026
Feb 4, 2026Beat
EPS Actual
$2.03
EPS Est.
$1.99
EPS Surpr.
+2.0%
Revenue
$13.34B
Q3 FY2025
Jul 17, 2025Miss
EPS Actual
$2.06
EPS Est.
$2.35
EPS Surpr.
-12.3%
Revenue
$14.84B
Q2 FY2025
Apr 29, 2025Miss
EPS Actual
$1.85
EPS Est.
$2.11
EPS Surpr.
-12.3%
Revenue
$13.62B
Q1 FY2025
Jan 31, 2025Miss
EPS Actual
$1.41
EPS Est.
$1.80
EPS Surpr.
-21.7%
Revenue
$13.56B
Q4 FY2024
Oct 29, 2024Miss
EPS Actual
$1.57
EPS Est.
$1.94
EPS Surpr.
-19.1%
Revenue
$13.17B
Q3 FY2024
Jul 18, 2024Miss
EPS Actual
$1.59
EPS Est.
$1.85
EPS Surpr.
-14.1%
Revenue
$12.59B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $2.30 | $2.42 | $2.49 | 1 |
| Q3 FY2027 | $2.29 | $2.41 | $2.48 | 1 |
| Q2 FY2027 | $2.25 | $2.37 | $2.44 | 1 |
| Q1 FY2027 | $2.13 | $2.25 | $2.32 | 1 |
| Q4 FY2026 | $2.12 | $2.24 | $2.30 | 1 |
| Q3 FY2026 | $2.16 | $2.28 | $2.35 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $14.2B | $14.8B | $15.1B | 2 |
| Q3 FY2027 | $14.1B | $14.6B | $15.0B | 2 |
| Q2 FY2027 | $13.8B | $14.4B | $14.7B | 2 |
| Q1 FY2027 | $13.3B | $13.8B | $14.1B | 2 |
| Q4 FY2026 | $14.2B | $14.8B | $15.1B | 2 |
| Q3 FY2026 | $14.0B | $14.5B | $14.9B | 5 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | Apr 28, 2026 | -5.2% | $145.00 | $145.00 | +0.00% |
| ▲ Q1 FY2026 | Feb 4, 2026 | +2.0% | $152.81 | $152.77 | -0.03% |
| ▼ Q3 FY2025 | Jul 17, 2025 | -12.3% | $118.66 | $118.66 | +0.00% |
| ▼ Q2 FY2025 | Apr 29, 2025 | -12.3% | $111.41 | $114.59 | +2.85% |
| ▼ Q1 FY2025 | Jan 31, 2025 | -21.7% | $101.26 | $101.26 | +0.00% |
| ▼ Q4 FY2024 | Oct 29, 2024 | -19.1% | $108.18 | $109.60 | +1.31% |
| ▼ Q3 FY2024 | Jul 18, 2024 | -14.1% | $110.00 | $110.00 | +0.00% |
| ▼ Q2 FY2024 | Apr 23, 2024 | -22.0% | $95.11 | $96.00 | +0.94% |
Q2 FY2026+0.00%
Report Date
Apr 28, 2026
EPS Beat/Miss
-5.2%
Price Before
$145.00
Price After
$145.00
Q1 FY2026-0.03%
Report Date
Feb 4, 2026
EPS Beat/Miss
+2.0%
Price Before
$152.81
Price After
$152.77
Q3 FY2025+0.00%
Report Date
Jul 17, 2025
EPS Beat/Miss
-12.3%
Price Before
$118.66
Price After
$118.66
Q2 FY2025+2.85%
Report Date
Apr 29, 2025
EPS Beat/Miss
-12.3%
Price Before
$111.41
Price After
$114.59
Q1 FY2025+0.00%
Report Date
Jan 31, 2025
EPS Beat/Miss
-21.7%
Price Before
$101.26
Price After
$101.26
Q4 FY2024+1.31%
Report Date
Oct 29, 2024
EPS Beat/Miss
-19.1%
Price Before
$108.18
Price After
$109.60
Q3 FY2024+0.00%
Report Date
Jul 18, 2024
EPS Beat/Miss
-14.1%
Price Before
$110.00
Price After
$110.00
Q2 FY2024+0.94%
Report Date
Apr 23, 2024
EPS Beat/Miss
-22.0%
Price Before
$95.11
Price After
$96.00
Avg Beat Reaction-0.03%
Avg Miss Reaction+0.73%
Beat Rate1 / 8 quarters
Largest Move+2.85% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: NVSEF ends December
Novartis AG (NVSEF) most recently reported earnings on April 28, 2026 for Q2 FY2026, posting EPS of $1.99 — missing the analyst consensus of $2.10 by -5.2%. The next NVSEF earnings date is expected around September 1, 2026.
Each quarter, investors track NVSEF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. NVSEF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
NVSEF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
NVSEF earnings · 5 questionsNovartis AG's next earnings report is expected around September 1, 2026. NVSEF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; NVSEF historically reports after market close (AMC).
NVSEF earnings datewhen is NVSEF earningsNVSEF next earnings datewhen does NVSEF report earningsNVSEF earnings calendar
▸ Source: FMP · Novartis AG SEC filings · US GAAP · Novartis AG SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026